Herbert Smith Freehills has partnered with the University of New South Wales on a practical training course for the firm’s Australian graduates that will allow them to start practicing sooner.
The nation’s peak body for barristers has lashed out at Prime Minister Scott Morrison for saying he has “never had much truck” with barristers during his political career and “didn’t care” if they disagreed with him about the need for a federal anti-corruption commission.
Moray & Agnew is facing a lawsuit by a former client who says the firm breached its duties by making an unauthorised $3.3 million transfer while representing him on an investment in a Melbourne storage facility development.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
The corporate regulator has taken Australian Mines to court after its managing director was allegedly caught lying at an investment conference about the value of an offtake agreement and funding for a project at its cobalt and nickel mine in Queensland.
Virgin Australia has struck back at a lawsuit by its former chief pilot alleging the airline sacked him for complaining of bullying and harassment by its CEO, saying it terminated the pilot’s employment after he was deemed medically unfit for his role.
Bayer has dropped its appeal to a ruling that quashed an extension for its patent covering an oral contraceptive, after the Full Court dealt drug makers a blow in two separate cases on how patent term extensions should be calculated.
Court-appointed receivers have told the court they should be trusted to determine the the best method for selling the Dover Heights mansion of Sydney fraudster Melissa Caddick, warning a public auction “could turn into a circus”.
A NSW developer says law firm Sparke Helmore should face a heftier damages bill for its negligence in failing to alert it to an imminent deadline in two land sale contracts worth a combined $1.5 million that were part of a troubled $30 million development.
Discount pharmacy Priceline cannot trade mark the signature bright pink that adorns it shopfront signs and awnings, an IP Australia delegate has found.